Onychomycosis is more common in diabetic than nondiabetic patients. It is more than a cosmetic problem, and diabetic patients have a greater risk of serious complications from the disease, including limb amputations. This article reviews the various diagnostic and therapeutic options available for onychomycosis with an emphasis on their roles in diabetic patients.

In Brief

Onychomycosis is more common in diabetic than nondiabetic patients. It is more than a cosmetic problem, and diabetic patients have a greater risk of serious complications from the disease, including limb amputations. This article reviews the various diagnostic and therapeutic options available for onychomycosis with an emphasis on their roles in diabetic patients.
Diagnosis of Onychomycosis

Clinical diagnosis
Infected nails appear thick, brittle, and discolored, often with a yellow hue. The nail plate may separate from the nail bed (onycholysis), and there may be inflammation of the skin near the nail edge (paronychial inflammation).

Onychomycosis has four classic clinical presentations in nails. Distal and lateral subungual infection is the most common type. In this pattern, the infection spreads proximally from the distal or lateral aspects of the nail, eventually raising the free edge of the nail plate and causing onycholysis and nail-plate thickening with subungal hyperkeratosis. The infection spreads proximally, causing yellow-brown discolorations. The most common organism is Trichophyton rubrum, followed by Trichophyton mentagrophytes. Candida species also cause this pattern of infection, as do molds such as the Aspergillus and Fusarium species. When complicated by infection with pigment-ed molds or bacteria such as Pseudomonas aeruginosa, the nails may appear dark green to black.

Proximal subungual infection is rare but more common in AIDS and immunosuppressed patients. In this pattern, the organisms invade via the proximal nail fold and spread to the nail matrix and then the deep surface of the nail plate.

White superficial onychomycosis is normally limited to the toenails. It presents with small well-defined superficial white patches on the nail that can merge to cover the entire nail. The diseased nails are brittle and may crumble. The vast majority of the cases are caused by the fungus Trichophyton interdigitale.

Total dystrophic onychomycosis is the most severe clinical manifestation of onychomycosis. In this form, the entire nail except for small fragments is destroyed, leaving a thickened nail bed.

Differential diagnosis
Only 57% of diabetic patients with abnormal-appearing toenails are confirmed to have onychomycosis. Many common disorders, including psoriasis, lichen planus, onychogryphosis, trauma, and idiopathic dystrophic nails are included in the differential diagnosis.

Psoriasis is the most common disorder that mimics onychomycosis and can show subungal hyperkeratosis, onycholysis, and onychodystrophy of the entire nail. Although psoriasis usually also has classic manifestations on other skin areas, it can be limited to the nails. Pitting and “oil drop” spots are far more common in psoriasis than in onychomycosis. Often in psoriasis, a “salmon patch,” an irregular yellow or pink area under the nail plate, will be present. This does not occur in onychomycosis.

Patients with lichen planus can have nail manifestations of the disease. Clinicians should carefully examine patients’ extremities and mucous membranes for the pathognomonic violaceous papules. Lichen planus can affect both fingernails and toenails, causing them to become brittle and ridged. Subungal hyperkeratosis and distal onycholysis may also occur.

Onychogryphosis is a severe deformation of the nail, most often affecting the great toes. The nail becomes very thick and discolored, resembling a ram’s horn. The nail bed can become hypertrophied. Onychogryphosis is most commonly caused by infrequent nail cutting and impaired peripheral circulation but may also be caused by trauma.

Repeated trauma to the nails, which can increase the risk of onychomycosis, can cause distal onycholysis with subsequent microbial colonization and altered pigmentation. In addition, a subungal hematoma from trauma may cause discolorations that can be confused with onychomycosis.

Laboratory diagnosis
The standard of care in diagnosing onychomycosis is clinical impression with one confirmatory laboratory finding, such as KOH-prepared direct microscopy, fungal culture, or histopathology with periodic acid Schiff (PAS) staining. It is important to verify clinical suspicion with laboratory investigations. One study compared the costs of empirically treating all patients with onychodystrophy with antifungals versus PAS staining all nails and treating only those with a positive histology. The study found that it was cost-effective to first diagnose and then treat empirically.

Samples for microscopy, culture, or histopathology can be collected from the nail plate or subungal debris. When collecting a sample, care should be taken with diabetic patients to avoid injuring the nail bed, which may increase the risk of secondary bacterial infection.

Histological examination. Most clinicians find it easiest to send nail clippings for histopathological evaluation with a PAS stain. Clippings are sent to the pathology laboratory in formalin, are embedded in paraffin, and are stained with haematoxylin, eosin, PAS, and toluidine blue. This method, also called “PATHPAS,” has been shown to be the most sensitive test. One study evaluated 105 patients with suspected onychomycosis using KOH preparation, culture, biopsy with PAS stain, and biopsy with calcofluor white stain. Biopsy with calcofluor white stain was considered the gold standard. The study found that the KOH preparation was 80% sensitive and 72% specific.
biopsy with PAS stain was 92% sensitive and 72% specific, and culture was 59% sensitive and 82% specific. 

**Direct examination.** Collected pieces are placed on a slide and treated with 10–30% KOH solution. The slide may be warmed over a flame to quicken the clearing of the nail and highlight the fungal features. Some recommend a combination of KOH and dimethylsulfoxide for clearer and faster results. Onychomycosis caused by dermatophytes can be diagnosed based on the appearance of long, regularly-shaped hyphae. If yeasts are the etiological agent, the appearance of budding spores can often be seen. Although the appearance of the nail may provide clues to the etiological agent, it cannot be used to diagnose the agent. 

**Culture.** Culture alone without clinical manifestations should not be used to diagnose onychomycosis. Cultures may be positive without a truly invasive infection because of contamination with comorbid onychodystrophy. For culture, samples from the nail plate and subungual keratosis should be placed in Sabouraud’s agar and incubated at 26º C for 7–14 days. Antibiotics in the agar prevent the growth of coexisting bacteria. If possible, samples should be placed on agar both with and without cycloheximide because cycloheximide inhibits the growth of most nondermatophytes. Unfortunately, culture is less sensitive than direct microscopy, especially when a patient has already been given treatment. However, culture is the only method available for identification of the specific pathogen, which may be helpful in the choice of therapy, particularly if the nails do not respond to therapy with oral terbinafine (discussed below). 

**Treatment of Onychomycosis in Diabetes**

The treatment of onychomycosis in diabetic patients is the same as in patients without diabetes. Toenails grow at one-third to one-half the rate of fingernails and thus need to be treated longer. Elderly diabetic patients’ nails may grow even slower and require a longer duration to treat. Several modalities can be used for the treatment of onychomycosis in diabetic patients: topical therapy, systemic therapy, combination therapy, and nail removal. Patients > 55 years of age may have a higher rate of relapse. In addition, patient education is vital to reduce the risk of recurrence. Many studies have compared the mycological cure rates, recurrence rates, and cost-effectiveness of the various treatment options. Although it has been shown that diabetic patients with onychomycosis have a higher rate of complications and infections than diabetic patients without onychomycosis, to our knowledge, no study has compared treatment options with outcomes such as diabetic complications or secondary infections. 

**Topical therapy**

There are three classes of topical antifungal creams: polyenes (e.g., nystatin), imidazoles (e.g., clotrimazole), and allylamines-benzylamines (e.g., terbinafine). All three are active against Candida, but only imidazoles and allylamines-benzylamines are active against dermatophytes. In general, topical therapy is not adequate for clearing nail infections, probably because of inadequate penetration of the medication into the affected tissues and nail bed. The exception to this is superficial white onychomycosis, which is easily treated with a topical agent because the organism grows on the upper nail plate rather than in the nail bed. 

Antifungal nail lacquers are available for treating onychomycosis and penetrate the nail better than creams and gels. One lacquer contains the active ingredient amorolfine, which is in a new class of antifungals, the morpholines. Another lacquer contains ciclopirox, which has a broader spectrum of activity. Nail lacquers are applied daily for 48 weeks, and once-weekly removal with nail polish remover is required. Mycological cure rates (negative results on microscopy and fungal culture) in U.S. studies have been as high as 36%. 

Topical antifungals alone do have a place for the reduction of relapses and reinfection once the initial infection has been fully treated. One author recommends using a miconazole nitrate 2% powder every 3 days to the web spaces to prevent relapses once the initial infection has been completely treated. 

**Oral therapy**

Many studies have evaluated systemic treatments for onychomycosis in the general population. However, diabetic patients with onychomycosis pose a special problem because they frequently take other medicines and have other health problems. 

Oral agents (summarized in Table 1) are absorbed via the circulation through the nail bed and take ~ 7 days to reach minimal inhibitory concentration (MIC). Once administration of the drug is discontinued, it can remain active in the nail for up to 90 days, and the nail does not need to be completely clear before the medication is stopped. 

Griseofulvin was the standard oral therapy for onychomycosis for > 30 years. However, it has a narrow therapeutic window and significant adverse reactions. It also has several interactions with other drugs and is active only against dermatophytes, with a cure rate of < 40%. For these reasons, it is rarely used today to treat onychomycosis. 

The imidazole class of medications is active against most of the organisms that cause onychomycosis. However, they are not approved for the treatment of onychomycosis in the United States. Ketoconazole is slightly more efficacious than griseofulvin but also has many adverse effects and drug interactions. It is rarely used to treat onychomycosis today. Fluconazole, 300 mg once a week for 6 months, is more efficacious and has been shown to be safe. 

Itraconazole, a triazole antifungal, binds more specifically to fungal cytochrome P-450 than other azoles, reducing the incidence of side effects. It is active against dermatophytes.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Organisms</th>
<th>Dosage</th>
<th>Length of Treatment</th>
<th>Common Side Effects</th>
<th>Common Drug Interactions</th>
<th>Monitoring/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Griseofulvin</td>
<td>Dermatophytes</td>
<td>500–1,000 mg daily</td>
<td>Until infection clears</td>
<td>Rash</td>
<td>Warfarin</td>
<td>Liver function tests</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Urticaria</td>
<td>Barbiturates</td>
<td>Renal function tests</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nausea</td>
<td>Oral contraceptives</td>
<td>Complete blood count every 6–8 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Vomiting</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diarrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Headache</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluconazole</td>
<td>Dermatophytes, some nondermatophyte molds, Candida spp.</td>
<td>150–300 mg weekly</td>
<td>Fingernails: 6–9 months</td>
<td>Nausea</td>
<td>Cimetidine</td>
<td>Pretreatment liver function test in patients with known hepatic abnormality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Headache</td>
<td>Hydrochlorothiazide</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rash</td>
<td>Tolbutamide</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Vomiting</td>
<td>Glipizide</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diarrhea</td>
<td>Glyburide</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Headache</td>
<td>Phenytoin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rash</td>
<td>Theophylline</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diarrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Headache</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diarrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Headache</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diarrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Headache</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diarrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Dermatophytes, some nondermatophyte molds, Candida spp.</td>
<td>Pulse: 200 mg twice daily for 1 week each month</td>
<td>Fingernails: 6 weeks</td>
<td>Headache</td>
<td>Statins</td>
<td>Pretreatment liver function test in patients with known hepatic abnormality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diarrhea</td>
<td>Benzdiazepines</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dyspepsia</td>
<td>Terfenadine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Flatulence</td>
<td>Carbamazepine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Abdominal pain</td>
<td>Anticonvulsants</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dizziness</td>
<td>Antacids</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rash</td>
<td>H2-blockers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Proton pump inhibitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Erythromycin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clarithromycin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Digoxin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Venpamid</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Oral hypoglycemics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Buspirone</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Methylprednisolone</td>
<td></td>
</tr>
<tr>
<td>Terbinafine</td>
<td>Dermatophytes, some nondermatophyte molds, NOT Candida spp.</td>
<td>250 mg daily</td>
<td>Fingernails: 6 weeks</td>
<td>Gastrointestinal disturbance</td>
<td>Caffeine</td>
<td>Pretreatment liver function test in patients with known hepatic abnormality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rash</td>
<td>Theophylline</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nausea</td>
<td>Warfarin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diarrhea</td>
<td>β-Blockers</td>
<td></td>
</tr>
<tr>
<td>FDA, U.S. Food and Drug Administration</td>
<td></td>
<td></td>
<td></td>
<td>Taste disturbance</td>
<td>Cimetidine</td>
<td></td>
</tr>
</tbody>
</table>
and Aspergillus but not Scytalidium, a mold. Because it is lipid-soluble, it remains in the nail plate long after the drug is discontinued. It has been detected 6 months after discontinuation after a 3-month course. Using 200 mg daily for 3 months achieved a mycological cure rate of 79% 6 months after therapy.

Because of the high cost of itraconazole, a pulse regimen has been formulated and tested. Pulse treatment involves using 200 mg twice daily for 1 week during each of 2 months in fingernails and 3 months in toenails. Pulse therapy has been reported to be just as effective as continuous therapy with fewer adverse events and half the cost.

Azole antifungals, including itraconazole and fluconazole, have been shown to elevate levels of oral hypoglycemic drugs. Nevertheless, systemic therapy with itraconazole has been found to be safe and effective for use in diabetic patients at a dose of 200 mg twice daily. No statistically significant changes in hemoglobin A1c levels have been noted in diabetic patients receiving pulse itraconazole for 3 months.

Terbinafine, an allylamine antifungal drug, is the first-line agent for treating onychomycosis. Unlike itraconazole’s wide spectrum of activity, terbinafine is only active in vivo against dermatophytes and does not treat Candida or mold species. Terbinafine, 250 mg once daily for 3 months, has been shown to achieve a mycological cure rate of 82% in toenail onychomycosis and 71% in fingernail onychomycosis. In one multicenter trial, 89 patients with diabetes (both insulin dependent and non–insulin dependent) and onychomycosis were treated with continuous oral terbinafine, 250 mg for 12 weeks, and were followed for 36 weeks posttreatment. After 48 weeks, a mycological cure rate of 73% was achieved. There were no reported episodes of hypoglycemia.

Another study of 81 diabetic patients with onychomycosis found equal efficacy of terbinafine in individuals with and without diabetes. Pulse therapy with terbinafine has not been shown to be as efficacious as continuous therapy.

Terbinafine does not have any significant interactions with oral hypoglycemic drugs. One study examining the safety and efficacy of terbinafine found that although 9.1% of diabetic subjects had serious adverse events while on terbinafine, no causal relationship between the drug and the events could be found. It was concluded that terbinafine is relatively safe in diabetic patients and is acceptable for the long-term maintenance of healthy nails in diabetic patients.

Studies comparing continuous terbinafine and continuous itraconazole have shown mixed results. One study found a 73% mycological cure rate for continuous terbinafine compared with 45.8% in continuous itraconazole for 12 weeks. Both drugs were well tolerated. Another study comparing continuous terbinafine and pulse itraconazole in elderly patients for 12 weeks plus an additional 4 weeks, if needed, after 6 months found a mycological cure rate for continuous terbinafine of 64% compared with 62.7% for pulse itraconazole. A second study of 496 patients with onychomycosis comparing continuous terbinafine with pulse itraconazole found that after 72 weeks in groups who were treated for 12 weeks, 75.7% of the terbinafine group achieved a mycological cure compared with 38.3% in the itraconazole group. In groups who were treated for 16 weeks, 80.8% of the terbinafine group achieved a mycological cure compared with 49.1% in the itraconazole group. A third study looked at long-term cure and relapse rates in continuous terbinafine compared with pulse itraconazole for 12 and 16 weeks. After 5 years, 47% of the terbinafine group compared with 13% of the itraconazole group still had negative mycology.

The newer antifungal agents, including terbinafine and itraconazole, rarely cause serious adverse reactions. Common adverse reactions occurring while patients took terbinafine included headache (12.9%), diarrhea (5.6%), rash (5.6%), and dyspepsia (4.3%). Liver enzyme abnormalities occurred in 3.3%. Common adverse reactions occurring while patients took itraconazole to treat onychomycosis of the toenails included headache (10%), rhinitis (9%), upper respiratory tract infection (8%), and sinusitis (7%). Liver enzyme elevations caused discontinuation of therapy in 4%. With both agents, the frequency of adverse events is comparable to placebo. The manufacturer of terbinafine recommends obtaining pretreatment liver function tests in all patients and monitoring a complete blood count in immunosuppressed patients receiving terbinafine for > 6 weeks.

Combining oral and topical antifungals is a newly developed treatment option that increases the likelihood of a cure. One study showed improved efficacy of terbinafine when combined with topical amorolfine. Another showed improved efficacy of continuous itraconazole...
when combined with topical amorolfin. Yet another compared three groups of patients: those who received terbinafine (4 weeks on, 4 weeks off) and 48 weeks of topical ciclopirox; those who received continuous terbinafine for 12 weeks and 48 weeks of ciclopirox; and those who received only 12 weeks of continuous terbinafine without topical antifungal medicine. Mycological cure was seen in 66.7, 70.4, and 56.0%, respectively. Another study found a mycological cure rate of 88.2 versus 64.7% when continuous terbinafine for 16 weeks was combined with topical ciclopirox for 9 months.

**Nail removal, avulsion**
Removal of diseased nails can be used as an adjunctive therapy but not as the sole therapy for onychomycosis. Surgical nail avulsion is rarely used to treat onychomycosis in diabetic patients because of their increased risk for secondary infections, gangrene, and poor wound healing. However, in severe or refractory cases, nail removal may be used. It may also be used when oral therapy is contraindicated or ineffective.

**Education**
High-risk diabetic patients, especially those with peripheral neuropathy or peripheral vascular disease, need to be educated about proper foot and leg examinations. In patients with a history of onychomycosis, it is especially important to examine the web spaces, heels, and perionychium for any breaks in the skin. It is important to stress that patients cannot rely solely on discomfort or pain because of decreased sensation.

**Conclusion**
Onychomycosis is an important cause of morbidity in diabetic patients, increasing their risks for limb amputation and local and systemic secondary bacterial infections. Because onychomycosis is more common in diabetic patients and can complicate the disease, clinicians must be vigilant in its diagnosis and complete in its treatment.

The most sensitive method for diagnosis is pathology with PAS staining. Culture is also important to guide the choice of therapy. Currently, the most effective therapy is 250 mg of oral terbinafine daily for 12 weeks, possibly with concomitant topical therapy with a nail lacquer, such as amorolfine or ciclopirox. Patients should be treated until mycological cure is achieved, and they must be followed closely for recurrent infection. If the causative organism is a yeast or mold, pulse itraconazole should be used instead. After treatment, suppressive topical therapy may be used, such as miconazole nitrate 2% powder every 3 days. In addition, patient education, including proper foot and toe examinations, is essential to prevent relapses and complications.

**REFERENCES**


28. SINGH G, HANNEF NS, UDAY A: Nail changes
and disorders among the elderly. Indian J Dermatol Venereol Leprol 71:386–392, 2005